Phase 2 N=43 Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Prostatic Neoplasms
Primary: Number of Patients With Immunological Response — 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Sphingomyelin Lipidosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)…
Phase 2 N=32 Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
Mycobacterium Infections, Nontuberculous
Primary: Number of Participants With Sputum Culture Conversion to Negative — 2; 3 Participants
Phase 2 N=136 Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Parkinson Disease
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Study Drug — 9.1; 17.8; 19.1 Percentage of participants
Phase 2 N=45 Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Electromyography Measures of Disease Progression. — -39.6; -31.8 percent change — p=0.4304
Phase 2 N=119 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald] — -0.83; -59.07 percent…
Phase 2 N=47 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Advanced Bladder Urothelial Carcinoma · Advanced Ureter Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma
Primary: Objective Response Rate (ORR) — 3; 4; 0; 2 Participants — p=0.428
Phase 2 N=48 A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
Hepatitis B, Chronic
Primary: Percentage of Participants With a Reduction of at Least 2 log10 International Unit/Millilitres (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels From Baseline to…
Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Phase 2 N=79 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Metastatic Endometrial Cancer
Primary: Progression Free Survival (PFS) — 28.1; 8.7 months
Phase 2 N=54 Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Asthma, Aspirin-Induced
Primary: Change From Baseline in Sinonasal Outcome Test-22 Score — -6.7; -13.7 units on a scale
Phase 2 N=87 A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Incidence of CMV Disease or CMV Viremia — 29; 9; 26 Participants
Phase 2 N=16 Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Locally Advanced Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants Who Successfully Completed Planned Treatment — 15 Participants
Phase 2 N=140 Repurposing Anti-TNF for Treating Dupuytren's Disease
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Phase 2 N=186 Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
Non Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 10.9; 10.9 Month — p=0.124